Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Drug Resistance Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for YBX1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YBX1 Full-Length / Cold Shock Domain (CSD) Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View YBX1 Products |
| Gene Delivery | YBX1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View YBX1 Products |
| Benchmark Ab | Anti-YBX1 (Sequence of Clinical Reference Antibody) Recombinant positive control. |
View YBX1 Products |
| Validator | YBX1 siRNA Set For knockdown verification. |
View YBX1 Products |
| Related Target A | EGFR YBX1 activation drives resistance to EGFR tyrosine kinase inhibitors (TKIs). |
View EGFR Products |
| Related Target B | ABCB1 Direct downstream transcriptional target of YBX1 mediating multidrug resistance. |
View ABCB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular targeting & CSD domain specificity screening | Recombinant YBX1 Cold Shock Domain (CSD) fragments available with >95% purity |
| Phosphorylation-dependent activity assays (Ser102) | Phospho-mimetic (S102D) and phospho-resistant (S102A) mutant proteins strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live YBX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for YBX1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors, PROTACs, and RNA-targeting modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of YBX1 nucleic acid binding and its upstream phosphorylation pathways to overcome chemotherapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic Institutes, Biotech Consortia | Triple-Negative Breast Cancer, Glioblastoma | Selectivity Assay (Need Mutant vs WT CSD Domain Proteins) |
| RNA Therapeutics (siRNA/ASO) | Oligonucleotide Biotech Developers | Refractory Solid Tumors, Drug-Resistant Cancers | Knockdown Validation (Need High-specificity siRNA & Lentivirus) |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Prostate Cancer, Metastatic Melanoma | Ubiquitination & Binding Assays (Need High-Purity Full-Length YBX1) |